This stock is no longer traded. It was delisted on July 21, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving selectivity and addressing resistance mechanisms. Its current programs center on non-small cell lung cancer, including therapies for ROS1-positive and ALK-positive disease, as well as a HER2-altered program in early clinical development. Nuvalent’s work is positioned within the oncology sector, where it contributes to the development of targeted medicines intended to support more durable responses and better tolerability across patient populations.
WebsiteOne Broadway
Cambridge, MA, 02142
United States
The latest articles about NUVL.
EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding fo
GSK (GSK) has kicked off a six-tranche dollar bond sale to help refinance bridge funding for its $10
Summary of Jun 10's posts. Generated by AI.
Summary of Jun 9's posts. Generated by AI.
Summary of Jun 10's posts. Generated by AI.
Investors talking about NUVL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.